Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
Yoshio Nakamura(Keio University), Naoya Yamazaki(Tokyo National Hospital), Keiji Tanese(Toho University), Noboru Yamamoto(Tokyo National Hospital), Arata Tsutsumida, Takeru Funakoshi(Keio University), Akira Takahashi, Kenjiro Namikawa(Tokyo Metropolitan Komagome Hospital), Masayuki Amagai(Keio University), Takayuki Abe(Keio University), Shigehisa Kitano(The Cancer Institute Hospital)
Cited by 160
Related Papers
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Inflammation-free, gas-permeable, lightweight, stretchable on-skin electronics with nanomeshes
|Nature Nanotechnology|2017|1.1k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k